Studying the right cell in acute myelogenous leukemia: Dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells"

Cell Cycle

Volumn 5, Issue 23, 2006, Pages 2769-2777

  Kornblau, Steven M ^a   Yi, Hua Qiu ^a   Bekele, B N ^a   Cade, Jenny Straka ^a   Zhou, Xian ^a   Harris, David ^a   Jackson, C Ellen ^a   Estrov, Zeev ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AML; BAX; BCL2; pERK2; PKC ; Prognostic impact; Signal transduction pathways; Survivor cells

Indexed keywords

ADULT; AGED; ARTICLE; CELL KILLING; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; WESTERN BLOTTING;

EID: 33845417611     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.23.3507     Document Type: Article

References (25)

1. Blagosklonny MV. Target for Cancer therapy: Proliferating cells or stem cell. Leukemia 2006; 20:385-91.
2. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using CDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5:3445-53.
3. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by CDNA microarray. Cancer Res 2000; 60:4161-6.
4. Stirewalt DL, Pogosova-Agadjanyan EL, Khalid N, Hare DR, Ladne PA, Sala-Torra O, Zhao LP, Radich JP. Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA. Genomics 2004; 83:321-31.
5. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKC. alpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin.Cancer Res 2000; 6:1401-9.
6. Quirke P, Dyson JF. Flow cytometry: Methodology and applications in pathology. J Pathol 1986; 149:79-87.
7. Darzynkiewicz Z, Bedner E, Li X, Gorczyca W, Melamed MR. Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res 2006; 249:1-12.
8. Wang RY, Weidner D, McQueen T, McMannis J, Korbling M, Champlin R, Andreeff M. Quantitative determination of Bcl-2 expression in AML cell lines and in normal and leukemic progenitor cell compartments by laser scanning cytometry: Comparison with flow cytometry and western blot. Hiddemann W, Buckner T, Ritter J, Unterhalt M. Acute Leukemias IX. Heidelberg, Germany: Springer, 2003:239-51.
9. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of Bcr-Abl MRNA in individual CML cells determined by in situ amplification: Enumeration of Bcr-Abl transcribing cells and correlation of transcript levels with disease stage. British Journal of Haematology 2001; 112:749-59.
10. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999; 5:1758-66.
11. Kornblau S, Milella M, Ball G, Qiu YH, Patel S, Ruvolo P, Estrov Z, Beran M, Kantarjian H, May WS, Andreeff M. ERK2 and Phospho-ERK2 are prognostic for survival in AML and complement the prognostic impact of BAX and BCL2. Blood Vol 2006; 108:2358-65.
12. Kornblau SM, Womble M, Cade JS, Lemker EM, Qiu YH. Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia 2005; 19:1550-7.
13. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108:2358-65.
14. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia [Letter]. Lancet 1977; 1:862-3.
15. Estrov Z, Black RA, Sleath PR. Effect of Interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 1995; 86:4594-602.
16. Snedecor GW, Cochran WG. Statistical Methods. 7 ed. Iowa: Iowa State University Press, 1980.
17. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39.
18. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972; 34:187-220.
19. Therneau TM, Grambsch PM. Modeling Survival Data. New York: Springer, 2000.
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7.
21. Bonnet D. Cancer Stem Cells: Lessons from leukemia. Cell Proliferation 2005; 38:357-61.
22. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RE, Kornblau SM, Reed C, Zhao S. Expression of Bcl-2 related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia 1999; 13:1881-92.
23. Kornblau S, Qui YH, Cade JS, Lemker EM, Giles F. Survivor cells predict which patients will respond to therapy with VNP4010M and Ara-C. Blood 2004; 104559a.
24. Tibes R, Qui YH, Coombes KR, Gold D, Mills GB, Kornblau SM. Classification of acute myelogenous leukemia (AML) based on patterns of signal transduction pathway (STP) and apoptosis regulating protein activation determined by reverse phase proteins arrays (RPPA). Blood 2005; 106:145a.
25. Tibes R, Qiu YH, Lu YL, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array (RPPA): Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC). Mol Cancer Ther 2006; In press.